What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?

Editorial

Open access

Maria Siddiqui and Gautam Borthakur

Expert opinion on pharmacotherapy, Vol.24(7), pp.775-778

05/03/2023

DOI: 10.1080/14656566.2023.2203320

PMID: 37070468

Files and links (1)

url

https://doi.org/10.1080/14656566.2023.2203320View

Published (Version of record) Open Access

cell cycle inhibitors

hypomethylating agents

intensive chemotherapy

lenalidomide

Myelodysplastic syndrome

Title: Subtitle: What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?
Creators: Maria Siddiqui - Baylor College of Medicine
Gautam Borthakur - The University of Texas MD Anderson Cancer Center
Resource Type: Editorial
Publication Details: Expert opinion on pharmacotherapy, Vol.24(7), pp.775-778
DOI: 10.1080/14656566.2023.2203320
PMID: 37070468
NLM abbreviation: Expert Opin Pharmacother
ISSN: 1465-6566
eISSN: 1744-7666
Publisher: Taylor & Francis
Number of pages: 4
Language: English
Date published: 05/03/2023
Academic Unit: Internal Medicine
Record Identifier: 9984848421502771

4 Record Views